Provided by Tiger Trade Technology Pte. Ltd.

EVEREST MED

43.960
-1.440-3.17%
Volume:2.45M
Turnover:108.52M
Market Cap:15.56B
PE:-12.30
High:45.900
Open:45.400
Low:43.840
Close:45.400
52wk High:77.550
52wk Low:36.300
Shares:354.00M
HK Float Shares:354.00M
Volume Ratio:1.68
T/O Rate:0.69%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-3.573
ROE:-23.04%
ROA:-9.09%
PB:3.60
PE(LYR):-12.30
PS:16.60

Loading ...

EVEREST MED Grants 1.2374 Million Stock Options and 530,300 Award Shares

Deep News
·
Oct 13

20 Billion Yuan Jiaxing Pharmaceutical Company Appoints New Chairman

Deep News
·
Oct 11

EVEREST MED (01952) Grants 1.2374 Million Stock Options and 530,300 Reward Shares

Stock News
·
Oct 10

BRIEF-Everest Medicines's Wei Fu Ceases To Be Chairman

Reuters
·
Oct 10

EVEREST MED (01952): Wu Yifang Appointed as Executive Director and Chairman of the Board

Stock News
·
Oct 10

Everest Medicines announces new chairman and board changes effective October 2025

Reuters
·
Oct 10

Everest Medicines Ltd - Wei Fu Ceased to Be Chairman

THOMSON REUTERS
·
Oct 10

Everest Medicines - Yifang Wu Appointed as Executive Director, Chairman

THOMSON REUTERS
·
Oct 10

EVEREST MED (01952) Grants 74,000 Stock Options Under Post-IPO Option Plan

Stock News
·
Oct 02

Everest Medicines Announces New Share Option and Award Grants Under Updated Compensation Plan

Reuters
·
Oct 02

IIgANN 2025: Latest Real-World Studies Confirm NEFECON®'s Sustained Efficacy and Safety in Long-Term Targeted Treatment

Stock News
·
Sep 18

EVEREST MED (01952): NEFECON® to Present 7 Latest Real-World Data Studies at 18th International IgA Nephropathy Symposium

Stock News
·
Sep 15

EVEREST MED (01952) Issues 2.6061 Million Shares Under Pre-IPO Employee Stock Option Plan and Post-IPO Share Award Plan

Stock News
·
Sep 05

Everest Medicines Ltd. Files Next Day Disclosure to HKEX: Announces Increase of 2,607,338 New Shares, Priced at HKD 23.17

Reuters
·
Sep 05

EVEREST MED (01952) Mid-Year Review: Dual "5 Billion Blockbuster" Commercialization Certainty Drives Growth, Global Innovation Value Reaches New Heights

Stock News
·
Aug 30

Stock Track | Everest Medicines Plunges 5% After H1 Results Despite Revenue Growth

Stock Track
·
Aug 29

Everest Medicines' H1 Loss Narrows as Revenue Sees Sharp Rise

MT Newswires Live
·
Aug 29

Everest Medicines Reports 48% Revenue Increase to RMB 446 Million in H1 2025, Driven by NEFECON® and XERAVA® Sales Growth

Reuters
·
Aug 29

Everest Medicines Announces Interim Results for First Half of 2025

THOMSON REUTERS
·
Aug 29

EVEREST MED (01952) Reports Interim Results with Revenue of RMB446 Million, Up 47.96% Year-over-Year

Stock News
·
Aug 29